PLPeter Lange

Peter Lange

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Peter Lange has a total of 230 co-authors. Here are the top co-authors by number of shared publications:

  • Jørgen Vestbo

    Division of Immunology, Immunity to Infection and Respiratory Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK

    17 shared publications
  • Yunus Çolak

    Department of Respiratory Medicine, Copenhagen University Hospital – Herlev and Gentofte, Copenhagen, Denmark

    14 shared publications
  • Shoaib Afzal

    Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

    10 shared publications
  • Børge Grønne Nordestgaard

    The Copenhagen General Population Study, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark

    6 shared publications
  • Jacob Louis Marott

    The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen University Hospital, Frederiksberg, Denmark

    6 shared publications
  • Sandra Søgaard Tøttenborg

    Department of Occupational and Environmental Medicine, Copenhagen University Hospital–Bispebjerg and Frederiksberg, Copenhagen, Denmark

    6 shared publications

Latest Publications

  • Development and Validation of a Pre-COPD Score to Predict Incident COPD

    by Yunus Çolak, Surya P Bhatt, Gregory L Kinney, Richard Casaburi, Børge G Nordestgaard, Jørgen Vestbo, Peter Lange, Shoaib Afzal

    Rationale: The ability to predict progression from a pre-disease state in chronic obstructive pulmonary disease (COPD), pre-COPD, to overt COPD remains limited. Objective: To test the hypothesis that development of COPD can be predicted by characterizing pre-COPD and creating a simple pre-COPD score. Methods: We identified individuals without airflow obstruction, defined as pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC)≥0.70 and ≥lower limit of normal, from the Copenhagen General Population Study (CGPS)(N = 14,506), Copenhagen City Heart Study (CCHS)(N = 8673), and Genetic Epidemiology for COPD (COPDGene) Study(N = 2982). A pre-COPD score was developed in CGPS by assigning 1 point to each of smoking history≥10 pack-years, active smoking, any respiratory symptom, asthma, and pre-BD FEV1/FVC 0.70-0.75, and 4 points for pre-BD FEV1<80% predicted, indicating presence of Preserved Ratio Impaired Spirometry (PRISm), with external validation in CCHS and COPDGene. Participants were followed for 5-10 years for incident COPD, defined as pre-BD FEV1/FVC<0.70 and FEV1<80% predicted. Measurements and Main Results: During follow-up, COPD developed in 669 individuals (4.6%) in CGPS, 685 (7.9%) in CCHS, and 367 (12%) in COPDGene. In CGPS, 10-year incidence was 1.5% in the low-risk, 9.3% in the intermediate-risk, 24% in the high-risk, and 42% in the very high-risk category. Corresponding 5-year incidences were 3.7%, 7.3%, 12%, and 25% in CCHS, and 4.1%, 5.3%, 13%, and 31% in COPDGene, respectively. The pre-COPD score demonstrated good discrimination with areas under curve of 0.88 in CGPS, 0.76 in CCHS, and 0.81 in COPDGene. The pre-COPD score was also associated with exacerbations. Conclusions: The pre-COPD score is useful in predicting the onset of COPD with clinically relevant discrimination in three cohorts with different risk profiles.

  • Sex differences in COPD in relation to smoking exposure: a population-based cohort study

    by Peter Lange, Shoaib Afzal, Yunus Çolak, Børge G Nordestgaard

    Background Sex discrepancies in the association between smoking and development and prognosis of chronic obstructive pulmonary disease (COPD) are controversial. We tested the hypothesis that females compared with males are more susceptible to the detrimental effects of smoking in relation to COPD. Methods We identified 47 231 males and 57 806 females from the Copenhagen General Population Study. Smoking amount was assessed with sex interaction against COPD-related outcomes, including the cross-sectional association with airway obstruction, chronic bronchitis and dyspnoea, assessed using logistic regression analyses, and longitudinal association with exacerbation and mortality, assessed using Cox proportional hazard regression adjusted for potential confounders. Results The increase in risk of airway obstruction (N=7367), chronic bronchitis (N=9206) and dyspnoea (N=8541) with higher smoking amount was greater in females compared with males. During 15 years’ follow-up (median 9.3 years), the increase in risk of exacerbation (events=2756), respiratory mortality (events=711) and all-cause mortality (events=10 658) with higher smoking was greater for females compared with males. Compared with never-smokers, adjusted HRs for exacerbation increased from 4.64 (95% CI 2.83 to 7.61) in females with 10 pack-years to 41.6 (95% CI 28.8 to 60.2) in females with ≥50 pack-years, and from 2.21 (95% CI 0.92 to 5.32) in males with 10 pack-years to 23.7 (95% CI 12.9 to 43.5) in males with ≥50 pack-years. Corresponding HR increases for respiratory mortality were 2.04 (95% CI 1.27 to 3.26) to 11.1 (95% CI 7.39 to 16.8) in females and 1.09 (95% CI 0.62 to 1.92) to 5.66 (95% CI 3.96 to 8.11) in males, and for all-cause mortality, HR increases were 1.50 (95% CI 1.34 to 1.67) to 3.53 (95% CI 3.11 to 4.00) in females and 1.62 (1.45–1.81) to 2.94 (2.69–3.21) in males, respectively. Conclusions Females seem more susceptible to the detrimental effects of smoking in development and prognosis of COPD compared with males.


  • Susceptible Young Adults and Development of Chronic Obstructive Pulmonary Disease Later in Life

    by Yunus Çolak, Peter Lange, Jørgen Vestbo, Børge G. Nordestgaard, Shoaib Afzal

    Rationale: Chronic obstructive pulmonary disease (COPD) has its origin in early life, and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) proposes a predisease state termed “pre-COPD.” Objectives: We tested the hypothesis that susceptible young adults identified with chronic bronchitis and subtle lung function impairment will develop COPD later in life. Methods: We followed random individuals without COPD ages 20–50 years from two population-based cohorts from different smoking eras—the Copenhagen General Population Study from 2003 (N = 5,497) and the Copenhagen City Heart Study from 1976–1978 (N = 2,609)—for 10 and 25 years, for the development of COPD (FEV1/FVC <0.70) and COPD GOLD Stages 2–4 (additionally, FEV1 <80% predicted). Measurements and Main Results: After 10 years, 28% developed COPD and 13% developed COPD GOLD Stages 2–4 in individuals susceptible to COPD, compared with 8% and 1% in those without any susceptibility to COPD. Correspondingly, after 25 years, 22% versus 13% developed COPD and 20% versus 8% developed COPD GOLD Stages 2–4. More than half of incident COPD cases developed from a susceptible state. Compared with those without susceptibility to COPD, multivariable-adjusted odds ratios in those susceptible to COPD were 3.42 (95% confidence interval: 2.78–4.21) for COPD and 10.1 (6.77–15.2) for COPD GOLD Stages 2–4 after 10 years and were 1.54 (1.23–1.93) and 2.12 (1.64–2.73) after 25 years. The ability of a COPD risk score—consisting of the state of susceptibility to COPD with smoking and asthma as risk factors—to predict COPD later in life was high. Conclusions: Our study suggests the existence of a predisease state of COPD, which can be used for early identification of susceptible individuals at risk for COPD later in life.


  • Top Cited Papers
    Open Access

    Type-2 inflammation and lung function decline in chronic airway disease in the general population

    by Yunus Çolak, Shoaib Afzal, Jacob Louis Marott, Jørgen Vestbo, Børge Grønne Nordestgaard, Peter Lange

    Background: It is unclear if type-2 inflammation is associated with accelerated lung function decline in individuals with asthma and chronic obstructive pulmonary disease (COPD). We tested the hypothesis that type-2 inflammation indicated by elevated blood eosinophils (BE) and fraction of exhaled nitric oxide (FeNO) is associated with accelerated lung function decline in the general population. Methods: We included adults from the Copenhagen General Population Study with measurements of BE (N=15 605) and FeNO (N=2583) from a follow-up examination and assessed forced expiratory volume in 1 s (FEV 1 ) decline in the preceding 10 years. Based on pre- and post-bronchodilator lung function, smoking history and asthma at follow-up examination, participants were assigned as not having airway disease, asthma with full reversibility (AR), asthma with persistent obstruction (APO), COPD, and not classifiable airflow limitation (NAL). Results: FEV 1 decline in mL/year increased with 1.0 (95% CI 0.6 to 1.4, p1 decline in mL/year was 18 (95% CI 17 to 20) in those with BE1 declines were 24 (19–29), 33 (25–40) and 44 (31–56) in AR (0.002), 26 (14–37), 36 (12–60) and 56 (24–89) in APO (0.07), 32 (27–36), 31 (24–38) and 44 (24–65) in COPD (0.46), and 27 (21–33), 35 (26–45), and 37 (25–49) in NAL (0.10), respectively. Conclusions: Type-2 inflammation indicated by elevated BE and FeNO is associated with accelerated FEV 1 decline in individuals with chronic airway disease in the general population, and this association was most pronounced in an asthma-like phenotype.


  • Open Access

    Exacerbations Predict Severe Cardiovascular Events in Patients with COPD and Stable Cardiovascular Disease–A Nationwide, Population-Based Cohort Study

    by Anders Løkke, Ole Hilberg, Peter Lange, Rikke Ibsen, Gunilla Telg, Georgios Stratelis, Jesper Lykkegaard

    Objective: Patients with chronic obstructive pulmonary disease (COPD) commonly present with cardiovascular disease (CVD). We investigated the association between COPD exacerbations and major cardiovascular (CV) events in a COPD population with a history of CVD. Methods: This population-based and register-based cohort study identified all Danish COPD patients aged ≥ 40 years who visited a hospital-based, pulmonary outpatient clinic for COPD between 1st January, 2010, and 31st December, 2016, from a nationwide COPD registry. Patients with a history of a major CV event 36‒6 months prior to their COPD measurement date and no CV event 6 months before this date were included. During a 6-month assessment period, the risks of a new CV event (hospitalization with fatal/non-fatal stroke, myocardial infarction, or heart failure) and moderate and severe COPD exacerbations were evaluated. Odds ratios with 95% confidence intervals for CV events and death were estimated using adjusted logistic regression models. Results: Of the 1501 COPD patients included, 55% experienced a COPD exacerbation and 13% experienced both an exacerbation and a CV event during follow-up (6 months). The odds of a CV event were 1.5 times higher in patients with a moderate exacerbation and more than 6-times higher in those with a severe exacerbation vs patients with no exacerbation(s). The majority of CV events occurred within 30 days post exacerbation in patients who experienced both an exacerbation and a CV event. In total, 113 patients died during the study period: 28% of deaths were caused by CVD and 72% by reasons other than CVD, mostly COPD. Conclusion: In patients with known CVD, severe COPD exacerbations are associated with increased odds of major CV events that occur within 30 days post exacerbation, highlighting the need to prevent exacerbations in COPD patients with concomitant CVD to potentially improve both respiratory and CV health.


  • Open Access

    Time‐Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial

    by Mark T. Dransfield, Gerard J. Criner, David M. G. Halpin, MeiLan K. Han, Benjamin Hartley, Ravi Kalhan, Peter Lange, David A. Lipson, Fernando J. Martinez, Dawn Midwinter, et al.

    Background: The association between chronic obstructive pulmonary disease exacerbations and increased cardiovascular event risk has not been adequately studied in a heterogenous population with both low and high cardiovascular risk. Methods and Results: This post hoc analysis of the IMPACT (Informing the Pathway of COPD Treatment) trial (N=10 355 symptomatic patients with chronic obstructive pulmonary disease at risk of exacerbations) evaluated time‐dependent risk of cardiovascular adverse events of special interest (CVAESI) following exacerbations and impact of exacerbation history, cardiovascular risk factors, and study treatment on this association. Risk (time‐to‐first) of CVAESI or CVAESI resulting in hospitalization or death was assessed during and 1 to 30, 31 to 90, and 91 to 365 days after resolution of moderate or severe exacerbations. CVAESI risk was compared between the period before and during/after exacerbation. CVAESI risk increased significantly during a moderate (hazard ratio [HR], 2.63 [95% CI, 2.08–3.32]) or severe (HR, 21.84 [95% CI, 17.71–26.93]) exacerbation and remained elevated for 30 days following an exacerbation (moderate: HR, 1.63 [95% CI, 1.28–2.08]; severe: HR, 1.75 [95% CI, 0.99–3.11; nonsignificant]) and decreased over time, returning to baseline by 90 days. Risk of CVAESI resulting in hospitalization or death also increased during an exacerbation (moderate: HR, 2.46 [95% CI, 1.53–3.97]; severe: HR, 41.29 [95% CI, 30.43–56.03]) and decreased in a similar time‐dependent pattern. Results were consistent regardless of exacerbation history, cardiovascular risk at screening, or study treatment. Conclusions: Overall risk of cardiovascular events was higher during and in the 30 days following chronic obstructive pulmonary disease exacerbations, even among those with low cardiovascular risk, highlighting the need for exacerbation prevention and vigilance for cardiovascular events following exacerbations. Registration: URL: https://clinicaltrials.gov/ct2/show/NCT02164513 ; Unique identifier: NCT02164513


  • Open Access

    Disease Trajectories and Impact of One Moderate Exacerbation in Gold B COPD Patients

    by Anders Løkke, Ole Hilberg, Peter Lange, Rikke Ibsen, Georgios Stratelis, Sofie de Fine Licht, Jesper Lykkegaard

    Introduction: Studies have shown that exacerbation in chronic obstructive pulmonary disease (COPD) increases the risk of further exacerbations. Our aim was to investigate the impact of a single moderate exacerbation on the odds of subsequent exacerbations and death in GOLD B COPD patients. Methods: This hospital-based nationwide, cohort study in Denmark included all patients ≥ 40 years of age with an in- and/or outpatient ICD-10 J44 diagnosis (COPD Register, 2008– 2014). Index was date of first registered modified Medical Research Council (mMRC) score ≥ 2; baseline period was 12 months pre-index. At index, patients were grouped as: B0, no exacerbation; and B1, one moderate exacerbation during the previous year, and followed for three consecutive years in 2008– 2017 for development of moderate- (short-term use of prednisolone or prednisone) and severe (emergency visit or hospitalization) exacerbations and death. Using B0 as reference, the odds ratio (OR) for exacerbation and death in GOLD B1 was estimated with multinominal logistic regression and a Cox model estimated the hazard ratio for exacerbation accounting for recurrent events. Results: In total, 8,453 patients (mean age 70 years, 51% male) were included, of which GOLD B0 4,545 and GOLD B1 3,908 patients. During the 3-year follow-up, 34.1% and 24.9% of GOLD B0 and B1, respectively, had none or one moderate exacerbation whereas 61.9% and 71.2% of B0 and B1, respectively, had a severe trajectory with multiple moderate and/or a severe exacerbation or died. In B1 patients, the OR for 1 moderate, ≥ 2 moderate exacerbations, ≥ 1 severe exacerbation was 1.58 [CI 1.33– 1.87], 2.60 [2.19– 3.08], 2.08 [1.76– 2.45], respectively, and 1.85 [1.57– 2.17] for death compared with B0. Conclusion: One moderate exacerbation in COPD patients with high symptom burden increases the odds of subsequent exacerbations and death during the three following years. The results emphasize the importance of preventing exacerbations in GOLD B patients.


  • Open Access

    Exacerbation history, severity of dyspnoea and maintenance treatment predicts risk of future exacerbations in patients with COPD in the general population

    by Jacob Louis Marott, Yunus Çolak, Truls Sylvan Ingebrigtsen, Jørgen Vestbo, Børge Grønne Nordestgaard, Peter Lange


  • Top Cited Papers

    Trajectory of Preserved Ratio Impaired Spirometry: Natural History and Long-Term Prognosis

    by Jacob Louis Marott, Truls Sylvan Ingebrigtsen, Yunus Çolak, Jørgen Vestbo, Peter Lange

    Rationale: Natural history of preserved ratio impaired spirometry (PRISm), often defined as FEV1/FVC ⩾lower limit of normal and FEV1<80% of predicted value, is not well described. Objectives: To investigate the natural history and long-term prognosis of the following PRISm trajectories: persistent PRISm trajectory (individuals with PRISm both young and middle-aged), normal to PRISm trajectory (individuals developing PRISm from normal spirometry in young adulthood), and PRISm to normal trajectory (individuals recovering from PRISm in young adulthood by normalizing spirometry while middle-aged). Methods: We followed 1,160 individuals aged 20–40 years from the Copenhagen City Heart Study from 1976 to 1983 until 2001 to 2003 to determine their lung function trajectory; 72 had persistent PRISm trajectory, 76 had normal to PRISm trajectory, 155 had PRISm to normal trajectory, and 857 had normal trajectory. From 2001–2003 until 2018, we determined the risk of cardiopulmonary disease and death. Measurements and Main Results: We recorded 198 admissions for heart disease, 143 for pneumonia, and 64 for chronic obstructive pulmonary disease as well as 171 deaths. Compared with individuals with normal trajectory, hazard ratios for individuals with persistent PRISm trajectory were 1.55 (95% confidence interval, 0.91–2.65) for heart disease admission, 2.86 (1.70–4.83) for pneumonia admission, 6.57 (3.41–12.66) for chronic obstructive pulmonary disease admission, and 3.68 (2.38–5.68) for all-cause mortality. Corresponding hazard ratios for individuals with normal to PRISm trajectory were 1.91 (1.24–2.95), 2.74 (1.70–4.42), 7.61 (4.21–13.72), and 2.96 (1.94–4.51), respectively. Prognosis of individuals with PRISm to normal trajectory did not differ from those with normal trajectory. Conclusions: PRISm in middle-aged individuals is associated with increased risk of cardiopulmonary disease and all-cause mortality, but individuals who recover from PRISm during their adult life are no longer at increased risk.